Evidence map›Paper›PMID 40610783›Full record

ArticleUpdates in surgery2026

Liver resection following neoadjuvant immunotherapy: a single center retrospective study.

Vanja Podrascanin, Markus Ammann, Yawen Dong, Cornelius A Thiels, Susanne G Warner, Mark J Truty, Michael L Kendrick, Rory L Smoot, David M Nagorney, Patrick P Starlinger

Abstract read
PubMed Publisher
In one paragraph

Article in Updates in surgery, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. [Expert consensus on the clinical diagnosis and treatment of coagulation disorders related to liver disease].Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology · 2026
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Vanja PodrascaninDepartment of Surgery, Division of Hepatobiliary and Pancreas Surgery, Mayo Clinic, 200 First Street SW, Rochester, MN, USA.
Markus AmmannDepartment of Surgery, Division of Hepatobiliary and Pancreas Surgery, Mayo Clinic, 200 First Street SW, Rochester, MN, USA.
Yawen DongDepartment of Surgery, Division of Hepatobiliary and Pancreas Surgery, Mayo Clinic, 200 First Street SW, Rochester, MN, USA.
Cornelius A ThielsDepartment of Surgery, Division of Hepatobiliary and Pancreas Surgery, Mayo Clinic, 200 First Street SW, Rochester, MN, USA.
Susanne G WarnerDepartment of Surgery, Division of Hepatobiliary and Pancreas Surgery, Mayo Clinic, 200 First Street SW, Rochester, MN, USA.
Mark J TrutyDepartment of Surgery, Division of Hepatobiliary and Pancreas Surgery, Mayo Clinic, 200 First Street SW, Rochester, MN, USA.
Michael L KendrickDepartment of Surgery, Division of Hepatobiliary and Pancreas Surgery, Mayo Clinic, 200 First Street SW, Rochester, MN, USA.
Rory L SmootDepartment of Surgery, Division of Hepatobiliary and Pancreas Surgery, Mayo Clinic, 200 First Street SW, Rochester, MN, USA.
David M NagorneyDepartment of Surgery, Division of Hepatobiliary and Pancreas Surgery, Mayo Clinic, 200 First Street SW, Rochester, MN, USA.
Patrick P StarlingerDepartment of Surgery, Division of Hepatobiliary and Pancreas Surgery, Mayo Clinic, 200 First Street SW, Rochester, MN, USA. starlinger.patrick@mayo.edu.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Liver resection remains an important treatment approach in both primary and metastatic liver malignancies. However, the impact of neoadjuvant immune checkpoint inhibitor (ICI) therapy on surgical outcomes remains incompletely explored. This study aimed to evaluate safety and surgical and oncological outcomes of liver resections after neoadjuvant immunotherapy. This retrospective single-institution analysis included a total of 20 patients receiving immunotherapy (Pembrolizumab, Durvalumab or Atezolizumab) prior to hepatic resection at Mayo Clinic Rochester from February 2019 until October 2023. Surgical outcomes as well as radiological and pathological response were assessed. A total of 20 patients were identified. The cohort comprised primary liver cancer (n = 5), colorectal cancer liver metastasis (CRLM) (n = 4), and non-CRLM (n = 11). Overall, severe postoperative morbidity was observed in 4 patients, with 2 cases of post hepatectomy liver failure (PHLF Grade B) and no postoperative mortality within 90 days. Histopathological examination delineated complete pathological response (pCR) response in 10 out of 16 evaluated patients, of whom one experienced recurrence within our follow-up period. Radiological response did not correlate with pathological response. Neoadjuvant ICI therapy showed excellent pathological response rates in highly selected patients, while maintaining surgical safety and expected postoperative morbidity. Standard radiological assessment appears to be insufficient to predict pCR.

Indexed as

HepatectomyImmune Checkpoint InhibitorsImmunotherapyLiver NeoplasmsNeoadjuvant TherapyAdultAgedColorectal NeoplasmsFemaleHumansMaleMiddle AgedPostoperative ComplicationsRetrospective StudiesTreatment OutcomeImmune Checkpoint InhibitorsLiver resectionNeoadjuvant immunotherapyPathological responseRECIST-CriteriaSurgical safety

Identifiers

PMID40610783

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.